By Bryan Bottarelli Technical Options Expert Bryan Bottarelli explains that although Pfizer stock under-performed this year, a move by director Ronald Blaylock should be a signal to investors. Here’s what it tells us…
This year, shares of big pharma giant Pfizer (NYSE: PFE) are down 3%.
So far, they’ve been a big-time underperformer.
And that’s exactly why I found it very interesting that Pfizer Director Ronald Blaylock just made one of the biggest insider buys on Pfizer stock in years.
Earlier this month, on August 6, he paid more than $500,000 for 13,000 shares – at an average price of $38.55.
Barron’s says, “This makes it the largest …read more
